Bias in reporting efficacy and toxicity in breast cancer trials
A recent paper did an analysis of breast cancer studies published over the last 16 years. They evaluated 164 trials and looked at whether results re: the drug’s toxicity or overall survival rate was reported prominently in the abstract, within the article, or at all. They looked at who funded the work, the impact factor of the journal the work was published in, and most interestingly, whether the trial found positive or negative results.